Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single- chain variable fragment intrabodies

Human Gene Therapy

Volumn 10, Issue 9, 1999, Pages 1453-1467

  Mhashilkar, Abner M ^a   LaVecchio, Joyce ^a   Eberhardt, Bridget ^b   Porter Brooks, Julie ^b   Boisot, Saskia ^b   Dove, Jeffrey H ^c   Pumphrey, Carla ^a   Li, Xuguang ^b   Weissmahr, Richard N ^a   Ring, David B ^c   Ramstedt, Urban ^b   Marasco, Wayne A ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Virus Research Institute Inc Cambridge   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; GENE THERAPY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

EID: 0033542388     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017798     Document Type: Article

References (76)

1. AGUILAR-CORDOVA, E., CHINEN, J., DONEHOWER, L. A., HARPER, J. W., RICE, A. P., BUTEL, J. S., and BELMONT, J. W. (1995). Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. 2, 181-186.
2. ALBINI, A., SOLDI, R., GIUNCIUGLIO, D., GIRAUDO, E., BENELLI, R., PRIMO, L., NOONAN, D., SALIO, M., CAMUSSI, G., ROCKL, W., and BUSSOLINO, F. (1996). The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nature Med. 2, 1371.
3. BISWAS, D. K., AHLERS, C. M., DEZUBE, B. J., and PARDEE, A. B. (1993). Cooperative inhibition of NF-κB and Tat-induced super-activation of human immunodeficiency virus type 1 long terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 90, 11044-11048.
4. - SCID: Initial trial results after 4 years. Science 270, 475-180.
5. - immunodeficient patients. Science 270, 470-475.
6. BRENNER, M. K., RILL, D. R., MOEN, R. C., KRANCE, R. A., MIRRO, J., JR., ANDERSON, W. R., and IHLE, J. N. (1993a). Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341, 85-86.
7. BRENNER, M. K., RILL, D. R., HOLLADAY, M. ., HESLOP, H. E., MOEN, R. C., BUSCHLE, M., KRANCE, R. A., SANTANA, V. M., ANDERSON, W. F., and IHLE, J. N. (1993b). Gene marking to determine whether autologous marrow unfusion restores long-term haemopoiesis in cancer patients. Lancet 342, 1134-1137.
8. BUNNELL, B. R., MUUL, L. M., DONAHUE, R. E., BLAESE, R. M., and MORGAN, R. A. (1995). High-efficiency retroviral-mediated gene transfer into human and non-human primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 92, 7739-7743.
9. BUONAGURO, L., BARILLARI, G., CHANG, H. K., BOHAN, C. A., KAO, V., MORGAN, R., GALLO, R. C., and ENSOLI, B. (1992). Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66, 7159-7167.
10. BUONAGURO, L., BUONAGURO, F. M., GIRALDO, G., and ENSOLI, B. (1994). The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 68, 2677-2682.
11. CARPENTER, C. C. J., FISCHI, M. A., HAMMER, S. M., HIRSCH, M. S., JACOBSEN, D. M., KATZENSTEIN, D. A., MONTANER, J. S. G., RICHMAN, D. D., SAAG, M. S., SCHOOLEY, R. T., THOMPSON, M. A., VELLA, S., YENI, P. G., and VOLBERDING, P. A. (1997). Antiretroviral therapy for HIV infection in 1997. JAMA 277, 1962-1969.
12. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289.
13. CHANG, H.-K., GENDELMAN, R., LISZIEWICZ, J., GALLO, R. C., and ENSOLI, B. (1994). Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1. Gene Ther. 1, 208-216.
14. CHOTHIA, C., LESK, A. M., TRAMONTANO, A., LEVITT, M., SMITH-GILL, S. J., AIR, G., SHERIFF, S., PADLAN, E. A., DAVIES, D., TULIP, W. R., COLMAN, P. M., SPINELLI, S., ALZARI, P. M., and POLJAK, R. J. (1989). Conformations of immunoglobulin hypervariable regions. Nature (London) 342, 877-883.
15. CUPP, C., TAYLOR, J. P., KHALILI, K., and AMINI, S. (1993). Evidence for stimulation of the transforming growth factor β1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene 8, 2231-2236.
16. DAYTON, A. I., SODROSKI, J. G., ROSEN, C. A., GOH, W. C., and HASELTINE, W. A. (1986). The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44, 941-947.
17. DEEKS, S., LOFTUS, R., COHEN, P., CHIN, S., and GRANT, R. (1997). Incidence and predictors of virologie failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. 37th ICAAC, Toronto, Canada, September 28-October 1, 1997. [Abstract LB-2].
18. DHAWAN, S., PURI, R. K., KUMAR, A., DUPLAN, H., MASSON, J.-M., and AGGARWAL, B. B. (1997). Human immunodeficiency virus-1-Tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1. vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 90, 1535-1544.
19. DUH, E. J., MAURY, W. J., FOLKS, T. M., FAUCI, A. S., and RABSON, A. B. (1989). Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 86, 5974-5978.
20. EMILIANI, S., FISCHLE, W., OTT, M., VAN LINT, C., AMELLA, C. A., and VERDIN, E. (1998). Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J. Virol. 72, 1666-1670.
21. ENSOLI, B., GENDELMAN, R., MARKHAM, P., FIORELLI, V., COLOMBINI, S., RAFFELD, M., CAFARO, A., CHANG, H.-K., BRADY, J. N., and GALLO, R. C. (1994). Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature (London) 371, 674-680.
22. FEINBERG, M. B., BALTIMORE, D., and FRANKEL, A. D. (1991). The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. U.S.A. 88, 4045-4049.
23. FINZI, D., HERMANKOVA, M., PIERSON, T., CARRUTH, L. M., BUCK, C., CHAISSON, R. E., QUINN, T. C., CHADWICK, K., MARGOLICK, J., BROOKMEYER, R., GALLANT, J., MARKOWITZ, M., HO, D. D., RICHMAN, D. D., and SILICIANO, R. F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300.
24. FISHER, A. G., FEINBERG, M. B., JOSEPHS, S. F., HARPER, M. E., MARSELLE, L. M., REYES, G., GONDA, M. A., ALDOVINI, A., DEBOUK, C., GALLO, R. C., and WONG-STAAL, F. (1986). The trans-activator gene of HTLV-III is essential for virus replication. Nature (London) 320, 367-371.
25. FOLKS, T. M., JUSTEMENT, J., KINTER, A., DINARELLO, C. A., and FAUCHI, A. S. (1987). Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238, 800-802.
26. FOLKS, T. M., JUSTEMENT, J., KINTER, A., SCHNITTMAN, S., ORENSTEIN, J., POLI, G., and FAUCI, A. S. (1988). Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Immunol. 140, 1117-1122.
27. GOLDBERG, A. L. (1995). Functions of the proteasome: The lysis at the end of the tunnel. Science 268, 522-523.
28. GOLDSTEIN, G. (1996). HIV-1 Tat protein as a potential AIDS vaccine. Nature Med. 1, 960-964.
29. GULICK, R., MELLORS, J., HAVLIR, D., ERON, J., GONZALEZ, C., MCMAHON, D., RICHMAN, D., VALENTINE, F., JONAS, J., MEIBOHM, A., ISAACS, R., CONDRA, J., EMINI, E., and CHODAKEWITZ, J. (1997). Indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): Concurrent or sequential therapy in ZDV-experienced patients. 37th ICAAC, Toronto, Canada, September 28-October 1, 1997. [Abstract I-89].
30. HARRICH, D., ULICH, C., GARCIA-MARTINEZ, L. F., and GAYNOR, R. B. (1997). Tat is required for efficient HIV-1 reverse transcription. EMBO J. 16, 1224-1235.
31. HAUBRICH, R. H., FLEXNER, C., LEDERMAN, M. M., HIRSCH, M., PETTINELLI, C. P., GINSBERG, R., LIETMAN, P., HAMZEH, F. M., SPECTOR, S. A., and RICHMAN, D. D. (1995). A randomized trial of the activity and safety of RO 24-7419 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J. Infect. Dis. 172, 1246-1252.
32. HAVLIR, D. V., MARSCHNER, I. C., HIRSCH, M. S., COLLIER, A. C., TEBAS, P., BASSETT, R. L., IOANNIDIS, J. P. A., HOLOHAN, M. K., LEAVITT, R., BOONE, G., and RICHMAN, D. D. (1998). Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. The AIDS Clinical Trials Group Study 343 Team. N. Engl. J. Med. 339, 1261-1268.
33. HO, W.-Z., HAROUSE, J. M., RANDO, R. F., GÖNCZÖL, E., SRINIVASAN, A., and PLOTKIN, S. A. (1990). Reciprocal enhancement of gene expression and viral replication between human cytomegalovirus and human immunodeficiency virus type 1. J. Gen. Virol. 71, 97-103.
34. HOWCROFT, T. K., STREBEL, K., MARTIN, M. A., and SINGER, D. S. (1993). Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260, 1320-1322.
35. HSU, M.-C., DHINGRA, U., EARLEY, J. V., HOLLY, M., KEITH, D., NALIN, C. M., RICHOU, A. R., SCHUTT, A. D., TAM, S. Y., POTASH, M. J., VOLSKY, D. J., and RICHMAN, D. D. (1993). Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. U.S.A. 90, 6395-6399.
36. HUANG, L.-M., JOSHI, A., WILLEY, R., ORENSTEIN, J., and JEANG, K.-T. (1994). Human immunodeficiency viruses regulated by alternative trans-activators: Genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J. 13, 2886-2896.
37. HUANG, L., BOSCH, I., HOFMANN, W., SODROSKI, J., and PARDEE, A. B. (1998). Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol. 72, 8952-8960.
38. JAYARAMAN, K., FINGAR, S. A., SHAH, J., and FYLES, J. (1991). Polymerase chain reaction-mediated gene synthesis: Synthesis of a gene coding for isozyme c of horseradish peroxidase. Proc. Natl. Acad. Sci. U.S.A. 88, 4084-4088.
39. JOHNSON, V. A., and BYINGTON, R. E. (1990). Quantitative assays for virus infectivity. In Techniques in HIV Research. A. Aldovini and B. D. Walker, eds. (Stockton Press, Stockholm, NY) pp. 71-96.
40. KAO, S.-Y., CALMAN, A. F., LUCIW, P. A., and PETERLIN, B. M. (1987). Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (London) 330, 489-493.
41. LASPIA, M. F., RICE, A. P., and MATTHEWS, M. B. (1989). HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59, 283-292.
42. LI, C. J., WANG, C., FRIEDMAN, D. J., and PARDEE, A. B. (1995). Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 92, 5461-5464.
43. LI, C. J., UEDA, Y., SHI, B., BORODYANSKI, L., HUANG, L., LI, Y.-Z., and PARDEK, A. B. (1997). Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 94, 8116-8120.
44. LISZIEWICZ, J., SUN, D., GALLO, R. C., ENSOLI, B., and LORI, F. (1996). Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. Hum. Gene Ther. 7, 2209-2216.
45. MHASHILKAR, A. M., BAGLEY, J., CHEN, S. Y., SZILVAY, A. M., HELLAND, D. G., and MARASCO, W. A. (1995). Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14, 1542-1551.
46. MHASHILKAR, A. M., BISWAS, D. K., LAVECCHIO, J., PARDEE, A. B., and MARASCO, W. A. (1997). Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-tat single-chain intrabodies and NF-κB antagonists. J. Virol. 71, 6486-6494.
47. MILLER, A. D. (1994). Retroviral vectors. Central Top. Microbiol. Immunol. 158, 1-23.
48. MILLER, A. D., MILLER, D. G., GARCIA, J. V., and LYNCH, C. M. (1993). Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217, 581-599.
49. MITOLA, S., SOZZANI, S., LUINI, W., PRIMO, L., BORSATTI, A., WEICH, H., and BUSSOLINO, F. (1997). Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 90, 1365-1372.
50. MORGAN, R. A., CORNETTA, K., and ANDERSON, W. F. (1990). Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. Human Gene Ther. 1, 135-149.
51. 2) production by HIV. J. Immunol. 142, 531.
52. OTT, M., EMILIANI, S., VAN LINT, C., HERBEIN, G., LOVETT, J., CHIRMULE, N., MCCLOSKEY, T., PAHWA, S., and VERDIN, E. (1997). Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275, 1481-1485.
53. PIALOUX, G., RAFFI, F., BRUN-VEZINET, F., MEIFFREDY, V., FLANDRE, P., GASTAUT, J.-A., DELLAMONICA, P., YENI, P., DELFRAISSY, J.-F., and ABOULKER, J.-P. (1998). A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N. Engl. J. Med. 339, 1269-1276.
54. POLI, G., BRESSLER, P., KINTER, A., DUH, E., TIMMER, W. C., RABSON, A., JUSTEMENT, J. S., STANLEY, S., and FAUCI, A. S. (1990a). Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms. J. Exp. Med. 172, 151-158.
55. POLI, G., KINTER, A., JUSTEMENT, J. S., KEHRL, J. H., BRESSLER, P., STANLEY, S., and FAUCI, A. S. (1990b). Tumor necrosis factor-alpha functions in an autocrine manner in the induction of HIV expression. Proc. Natl. Acad. Sci. U.S.A. 87, 782-785.
56. POPIK, W., and PITHA, P. M. (1993). Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type 1. J. Virol. 67, 1094-1099.
57. + T-cells from HIV-infected individuals which express an intracellular antibody against HIV-1 gp 120 or tat. Hum. Gene Ther. 9, 487-496.
58. QUEEN, C., SCHNEIDER, W. P., SELICK, H. E., PAYNE, P. W., LANDOLFI, N. F., DUNCAN, J. E., AVDALOVIC, N. M., LEVlTT, M., JUNGHANS, R. P., and WALDMANN, T. A. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc. natl. Acad. Sci. U.S.A. 86, 10029-10033.
59. RIDDELL, S. R., ELLIOTT, M., LEWINSOHN, D. A., GILBERT, M. J., WILSON, L., MANLEY, S. A., LUPTON, S. D., OVERELL, R. W., REYNOLDS, T. C., COREY, L., and GREENBERG, P. D. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223.
60. ROCK, K. L. (1996). A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17, 131-137.
61. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. 71, 2740-2746.
62. SASTRY, K. J., REDDY, R. H. R., PANDITA, R., TOTPAL, K., and AGGARWAL, B. B. (1990). HIV-1 tat gene induces tumor necrosis factor-β (lymphotoxin) in a human B-lymphoblastoid cell line. J. Biol. Chem. 265, 20091-20093
63. SCALA, G., RUOCCO, M. R., AMBROSINO, C., MALLARDO, M., GIORDANO, V., BALDASSARRE, F., DRAGONETTI, E., QUINTO, I., and VENUTA, S. (1994). The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179, 961-971.
64. SIECZKOWSKI, L., CHANDRAN, B., and WOOD, C. (1995). The human immunodeficiency virus tat gene enhances replication of human herpes virus-6. Virology 211, 544-553.
65. SULLENGER, B. A., GALLARDO, H. F., UNGERS, G. E., and GILBOA, E. (1990). Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63, 601-608.
66. TADA, H., RAPPAPORT, J., LASHGARI, M., AMINI, S., WONGSTAAL, F., and KHALILI, K. (1990). Trans-activation of the JC virus late promoter by the Tat protein of type 1 human immunodeficiency virus in glial cells. Proc. Natl. Acad. Sci. U.S.A. 87, 3479-3483.
67. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 69, 4045-4052.
68. VISCIDI, R. P., MAYUR, K., LEDERMAN, H. M., and FRANKEL, A. D. (1989). Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246, 1606-1608.
69. VOGEL, J., HINRICHS, S. H., REYNOLDS, R. K., LUCIW, P. A., and JAY, G. (1988). The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature (London) 335, 606-611.
70. WEI, P., GARBER, M. E., FANG, S.-M., FISCHER, W. H., and JONES, K. A. (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451-462.
71. WESTENDORP, M. O., LI-WEBER, M., FRANK, R. W., and KRAMMER, P. H. (1994). Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J. Virol. 68, 4177-4185.
72. WESTENDORP, M. O., SHATROV, V. A., SCHULZE-OSTHOFF, K., FRANK, R., KRAFT, M., LOS, M., KRAMMER, P. H., DRÖGE, W., and LEHMANN, V. (1995). HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J. 14, 546-554.
73. WOFFENDIN, C., RANGA, U., YANG, Z.-Y., XU, L., and NABEL, C. J. (1996). Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. U.S.A. 93, 2889-2894.
74. WONG, J. K., HEZAREH, M., GÜNTHARD, H. F., HAVLIR, D. V., IGNACIO, C. C., SPINA, C. A., and RICHMAN, D. D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295.
75. YANG, X., GOLD, M. O., TANG, D. N., LEWIS, D. E., AGUILAR-CORDOVA, E., RICE, A. P., and HERRMANN, C. H. (1997). TAK. an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. U.S.A. 94, 12331-12336.
76. ZHOU, C., BAHNER, I. C., LARSON, G. P., ZAIA, J. A., ROSSI, J. J., and KOHN, D. B. (1994). Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-39.